Healthcare Industry - Medical - Pharmaceutical - Biotech in Incheon, Korea, South

South Korea is rapidly advancing its cell and gene therapy (CGT) ecosystem, with key milestones such as Curocell's Rimqarto becoming the first MFDS-approved cell therapy, and continued innovation from companies like Vaxcellbio and Rznomics advancing next-generation m ..

South Korea's mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in clinical-stage vaccines. Also, with the growing momentum of ARPA-H initiatives focused on personalized mRNA cancer therapies and strong government ba ..

South Korea is fast becoming the epicentre of targeted therapeutics innovation. To meet the growing demand for safer, more effective drugs with broader therapeutic windows that can improve on standard of care treatments and meet an unmet medical need, the World Advan ..

Amongst established global biopharma powerhouses like the US and China, how does South Korea carve out its own innovation leadership position? Through active government investment into AI and in silico capabilities, combined with a uniquely collaborative culture f ..

Korea is rapidly emerging as a global hub for CNS innovation, with advances spanning diverse modalities, BBB shuttling technologies and differentiated targets beyond Amyloid beta and tau. As a result, pharma and venture interest has surged, with 2026 already witnessi ..

The 5th World ADC Summit South Korea (9-11 June 2026 | Seoul) is Asia's premier meeting dedicated to accelerating next-generation antibody drug conjugate (ADC) development. As part of the broader World Targeted Therapeutics Summit South Korea, it sits alongside the W ..

Bispecifics and T-cell engagers are redefining the future of solid tumor treatment. With the landmark approvals of tarlatamab and ivonescimab, the spotlight is firmly on these modalities as powerful solutions for long-standing unmet needs. At the same time, the field ..

Welcome to the Inaugural RNA-Based Therapeutics and Vaccines Summit Asia Uniting RNA Therapeutic and Vaccine Developers from Across Asia Asia is booming in RNA innovation and partnerships towards commercial markets following key investments from the Korea Disea ..

Following Isen's groundbreaking $1B+ ADC deal with China-based Foreseen Biotechnology, the rapid rise of new companies, billions of dollars in investments, and a surge in partnerships involving Asian firms continue to capture the world’s attention. All eyes are now f ..

The year 2024 has been considered the 'coming of age' era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. This part of the world is taking the ADC industry by storm with high-profile dea ..

The 2023 PDA Aseptic Processing of Biopharmaceuticals Conference is back and it will focus on the manufacture of sterile drug products and patient-friendly applications. An exhibition will be held alongside the conference to provide delegates and industry partners al ..